# Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis

> **NCT01218581** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mansoura University** · enrollment: 32 (actual)

## Conditions studied

- the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis

## Interventions

- **DRUG:** received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)

## Key facts

- **NCT ID:** NCT01218581
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2010-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218581, "Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01218581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*